groups:relogio:research

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revision Previous revision
Next revision		 Previous revision
groups:relogio:research [2015/09/13 19:47] – relogiogroups:relogio:research [2016/06/22 11:12] (current) – removed schuppner
Line 1: Line 1:
-  
-====== research ====== 
  
- 
- 
-===== The Mammalian Circadian Clock  ===== 
- 
- 
- 
-All cells hold an internal clock able to generate daily rhythms. These endogenous rhythms are detected in 10% of all genes [1] and provide a way to react to external clues, to anticipate behaviour and to adapt molecular processes to specific day-times . Malfunctions of the circadian clock have been reported in the context of many diseases and disorders. Cancer is one such disease, although the mechanisms involved are not yet clear. Clock-controlled genes (CCGs) are involved in many molecular processes essential for malignant transformation of tumour cells [2]. The coupling of the circadian system to tumour progression is still an unexploited field of research. We use a systems biology approach involving wet-lab experiments, including genome wide screening of gene expression of human and murine cells  and tissues, bioinformatics and computational models,  to understand the dynamic interplay between cancer and the clock [3].  
- 
-{{ :groups:relogio:bild2.jpg?600|}} 
- 
-With such a methodology we aim to answer the following questions: 
- 
-How are the pathways, which connect the circadian clock to cancer, regulated? 
- 
-Is this regulation specific for different stages of tumour progression? 
- 
-Can a circadian signature for tumour progression be defined? 
- 
-With our research, we expect to be able to provide valuable insights into the mechanism of circadian regulation of tumourigenesis per se and to contribute to a better understanding of the cancer-clock system. As a perspective, work from our group  may contribute with valuable information to the improvement of diagnosis and prognosis in cancer, potentially leading to the identification of novel drug-targets and optimization of therapy. 
- 
- 
-1. T. Bollinger, U. Schibler, Swiss Med Wkly. (2014)  [[http://www.ncbi.nlm.nih.gov/pubmed/25058693|PMID: 25058693]] 
- 
-2. S. Sahar, P. Sassone-Corsi, Nat Rev Cancer 9, 886 (2009) [[http://www.ncbi.nlm.nih.gov/pubmed/19935677|PMID: 
-    19935677]] 
- 
- 
-3. A. Relógio, //et al//., PLoS Genet (2014) [[http://www.ncbi.nlm.nih.gov/pubmed/24875049|PMID: 24875049]]